Nanjing Xinjiekou halts plan to buy remaining Cordlife shares

The company is under investigation by the Ministry of Health.

Nanjing Xinjiekou, a substantial shareholder of Cordlife Group Limited, has cancelled its plans to acquire the cord-blood bank’s remaining shares.

In a bourse filing, in its eventh letter to Cordlife, Nanjing Xinjiekou said it is withdrawing from the potential offer due to risks misaligned with its investment criteria and business strategy.

The seventh letter follows the several earlier ones stating Nanjing Xinjiekou was still interested in buying over Cordlife’s share it does not own.

However, Nanjing Xinjiekou said it remains “fully committed to leveraging on its expertise and resources to help the company navigate through its current challenges and rehabilitate the group’s business”.

Cordlife’s Singapore operations remain suspended following the Ministry of Health’s (MOH) directive to stop the collection, testing, processing and storing of new cord blood for up to an additional three months effective 15 June or unless sooner approved by the Director-General of Health.

The MOH’s investigations are ongoing with no certainty on the outcome or when Cordlife’s suspension will be lifted.

Additionally, the Association of the Advancement of Blood & Biotherapies informed Cordlife on 15 August that it has withdrawn the company’s AABB accreditation for cord blood activities.

The association can accredit the company only after the MOH permits business resumption, the company resolves all issues, and several months of records are available for onsite inspection.

“The ongoing investigations by MOH, along with the fixed costs being incurred during the suspension of the Singapore operations of the company and its subsidiaries are expected to continue to have a negative financial impact on the Group's Singapore operations, which had been the Group's largest revenue contributor,” its filing said.

Cordlife recently recorded a net loss of $12.4m in the first half of the year compared to its corresponding period’s profit of $2.2m in 2023.

Follow the link s for more news on

Cordlife Group

Ministry of Health

healthcare

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia